144
Participants
Start Date
December 18, 2018
Primary Completion Date
February 9, 2024
Study Completion Date
June 1, 2028
KYMRIAH
FDA approved CD19-directed genetically modified autologous T cell immunotherapy comprised of autologous T cells
YESCARTA
CD19-directed genetically modified autologous T cell immunotherapy
Fludarabine 30mg/m2 4 doses
30 mg/m2 IV daily for 4 doses
Cyclophosphamide 500 mg/m2; 2 doses
500 mg/m2 IV daily for 2 doses starting with the first dose of fludarabine
Fludarabine 30mg/m2 3 doses
30 mg/m2 IV daily for 3 doses
Cyclophosphamide 500 mg/m2; 3 doses
500 mg/m2 IV daily for 3 doses starting with the first dose of fludarabine
Fludarabine 25mg/m2 3 days
25 mg/m2 i.v. daily for 3 days
Cyclophosphamide 250 mg/m2; 3 days
250 mg/m2 IV daily for 3 days starting with the first dose of fludarabine
Tecartus
TECARTUS is a CD19-directed genetically modified autologous T cell immunotherapy, binds to CD19-expressing cancer cells and normal B cells
Abecma, Intravenous Suspension
Infuse ABECMA 2 days after completion of lymphodepleting chemotherapy.
Cyclophosphamide 900 mg/m2; 1 day
Administer cyclophosphamide 900 mg/m2 over 60 minutes on the second day before infusion of TECARTUS
Breyanzi Injectable Product
Infuse BREYANZI 2 to 7 days after completion of lymphodepleting chemotherapy.
Masonic Cancer Center at University of Minnesota, Minneapolis
Masonic Cancer Center, University of Minnesota
OTHER